The New York Times published an article this week about Bayer, which is running a series of corrective advertisements about its birth control pill, Yaz. The FDA asked Bayer to run the corrective ads in response to previous advertisements for Yaz that claimed to also help with such sumptoms as pimples and premenstrual syndrome. The requirement from the FDA to run a corrective campaign is part of a new crackdown on deceptive consumer drug advertising. Given that the financial stakes are so high for drug companies, it likely won't be the last time the FDA has to ask a pharmaceutical company is asked to run a corrective advertising campaign.
You can see the article here.
What do you think?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment